Takeda Healthcare Philippines, Inc. and Otsuka-Solar Philippines, Inc., with the support of the Embassy of Japan in the Ph ...

The battle to drastically reduce, if not totally eradicate, dengue cases must involve yearlong efforts. It cannot be a ...

Takeda had hoped that Eohilia would be the ... The drugmaker has had mixed results from Wave1, with approvals for dengue fever vaccine Qdenga and post-transplant cytomegalovirus (CMV) therapy ...

Dengue is endemic in more than ... Two preventive vaccines have been approved to date – Sanofi’s Dengvaxia and Takeda’s Qdenga – but there is still a need for a drug treatment for patients ...

the same vectors that spread dengue and zika. The broad-based agreement includes early stage development to the final commercialisation of the vaccine. There is currently no vaccine to prevent or ...

"A safe and effective dengue virus vaccine is clearly the long-term solution, but more immediate strategies are urgently needed to combat the current dengue problem." There is reason to be ...

Biological scientists have uncovered how the dengue virus uses its envelope protein to capture human plasmin from a blood meal to enhance the permeability of the mosquito midgut for infection.

As of now, there are no dengue fever treatments approved by the ... Juliette Kim becomes first Korean CEO of global Takeda Group, 13th largest pharma Global pharmaceutical giant Takeda Group ...

Dengue virus infects up to 400 million people worldwide each year according to World Health Organization estimates, and no available treatments exist for this disease. ... Dengue Fever Infections ...

Since pertussis is one of the vaccine-preventable diseases on the rise, additional vaccine approaches are needed. These approaches include vaccination of newborns, additional booster doses for ...